Dianthus Therapeutics (DNTH) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Grifols S.A. (GRFS) over the past year, gaining 144.6% versus a loss of 21.8%. Over five years, DNTH leads with a -21.2% price change compared with -47.3% for GRFS. Grifols S.A. is the larger company by market cap ($5.10 billion vs $4.75 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | GRFS |
|---|---|---|
| Share price | $84.88 | $7.50 |
| Market cap | $4.75B | $5.10B |
| 1-day change | -0.61% | -0.27% |
| YTD return | +105.97% | -19.79% |
| 1-year return | +144.61% | -21.79% |
| 5-year return | -21.17% | -47.26% |
| P/E ratio (TTM) | — | 9.74 |
| Forward P/E | — | 5.20 |
| EPS (TTM) | $-4.24 | $0.77 |
| Dividend yield | 0.00% | 1.41% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | — |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $9.90 |
| 52-week low | $32.22 | $6.96 |
| Distance from 52-week high | -27.99% | -24.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +65.88% | +44.93% |
| Average volume | 825.33K | 583.27K |
| Shares outstanding | 55.93M | 258.22M |
| Employees | 92 | 25,258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed GRFS by 166.4 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
DNTH vs GRFS FAQ
Which is bigger, Dianthus Therapeutics or Grifols S.A.?
Grifols S.A. (GRFS) is larger, with a market capitalization of $5.10B compared with $4.75B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or GRFS?
DNTH returned +144.61% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Dianthus Therapeutics or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.41%, while Dianthus Therapeutics does not currently pay a regular dividend.
Are Dianthus Therapeutics and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.